Stella Pharma Corporation (TYO:4888)
431.00
-1.00 (-0.23%)
Nov 18, 2026, 10:00 AM JST
Stella Pharma Revenue
Stella Pharma had revenue of 83.00M JPY in the quarter ending September 30, 2026, a decrease of -23.15%. This brings the company's total for the last twelve months to 298.00M, down -69.96% year-over-year. In the fiscal year ending March 31, 2026, Stella Pharma had annual revenue of 323.00M, down -66.39%. That makes Stella Pharma the 42,548th largest company in the world by revenue and 3,854th in Japan.
Revenue (ttm)
298.00M
Revenue Growth
-69.96%
P/S Ratio
55.14
Revenue / Employee
6.34M
Employees
47
Market Cap
16.39B
Revenue by Geography
- China 629.97M 65.5%
- Japan 331.09M 34.5%
Fiscal year ended Mar 31, 2024 See the full Stella Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 323.00M | -638.00M | -66.39% |
| Mar 31, 2025 | 961.00M | 692.00M | 257.25% |
| Mar 31, 2024 | 269.00M | 40.00M | 17.47% |
| Mar 31, 2023 | 229.00M | 129.00M | 129.00% |
| Mar 31, 2022 | 100.00M | -105.00M | -51.22% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 5.79B |
| RaQualia Pharma | 3.90B |
| ReproCELL | 2.42B |
| Immuno-Biological Laboratories | 1.08B |
| AnGes | 962.00M |
| Carna Biosciences | 756.57M |
| Kubota Pharmaceutical Holdings | 16.00M |